Biopharma dealmaking in 2020.
作者信息
Giglio Patricia, Micklus Amanda
出版信息
Nat Rev Drug Discov. 2021 Feb;20(2):95-96. doi: 10.1038/d41573-021-00015-9.
PMID:33446884
Abstract
摘要
相似文献
1
Biopharma dealmaking in 2020.2020年生物制药交易情况。
Nat Rev Drug Discov. 2021 Feb;20(2):95-96. doi: 10.1038/d41573-021-00015-9.
2
Biopharma dealmaking in 2021.
Nat Rev Drug Discov. 2022 Feb;21(2):93-94. doi: 10.1038/d41573-022-00017-1.
3
Pool patents to get COVID vaccines and drugs to all.集中专利，让所有人都能获得新冠疫苗和药物。
Nature. 2021 Mar;591(7851):529. doi: 10.1038/d41586-021-00759-9.
4
Covid-19: an economic perspective on vaccinating the world.新冠疫情：全球疫苗接种的经济视角
BMJ. 2021 Jun 15;373:n1498. doi: 10.1136/bmj.n1498.
5
The costs of coronavirus vaccines and their pricing.新冠病毒疫苗的成本及其定价。
J R Soc Med. 2021 Nov;114(11):502-504. doi: 10.1177/01410768211053006. Epub 2021 Nov 3.
6
Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective.从博弈论角度激励富裕国家参与新冠疫苗全球获取机制（COVAX）
BMJ Glob Health. 2020 Nov;5(11). doi: 10.1136/bmjgh-2020-003627.
7
COVID-19 vaccines and treatments: When speed is necessary and not enough.新冠病毒疫苗与治疗方法：速度虽不可或缺，但仅有速度还不够。
Clin Transl Sci. 2021 Jul;14(4):1201-1205. doi: 10.1111/cts.13010. Epub 2021 Apr 9.
8
Merck moves into biotech.默克进军生物技术领域。
Nat Biotechnol. 2006 Jul;24(7):730. doi: 10.1038/nbt0706-730.
9
Market watch: Sales of biologics to show robust growth through to 2013.市场观察：生物制剂销售额到2013年将呈现强劲增长。
Nat Rev Drug Discov. 2009 Nov;8(11):837. doi: 10.1038/nrd3040.
10
Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.在考虑豁免新冠病毒知识产权时，无需担心制药行业的利润。
BMJ. 2022 Jan 31;376:e067367. doi: 10.1136/bmj-2021-067367.
引用本文的文献
1
Value drivers of development stage biopharma companies.生物制药开发阶段公司的价值驱动因素。
Eur J Health Econ. 2022 Nov;23(8):1287-1296. doi: 10.1007/s10198-021-01427-5. Epub 2022 Jan 17.
Zotero 插件